GENFLOW BIOSCIENCES PLC Logo

GENFLOW BIOSCIENCES PLC

Develops gene therapies to slow aging and treat age-related diseases in humans and dogs.

GENF | IL

Overview

Corporate Details

ISIN(s):
GB00BP2C3V08
LEI:
213800HVOFXRXVEGDN62
Country:
United Kingdom
Address:
6 HEDDON STREET, W1B 4BT LONDON
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Genflow Biosciences PLC is a preclinical biotechnology company focused on longevity science. Founded in 2020, the firm develops gene therapies designed to halt or slow the aging process and treat age-related diseases in both humans and dogs. Its core therapeutic approach centers on its lead compound, GF-1002, which delivers a centenarian variant of the SIRT6 gene, a key gene associated with exceptional longevity. The company's mission is to extend healthspan by intervening directly in the biological mechanisms of aging, with its programs demonstrating promising preclinical results.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 11.6 KB
2025-10-22 08:00
Regulatory News Service
Second European Patent Application
English 17.8 KB
2025-10-20 08:00
Regulatory News Service
Recognition of Patentability of Claims
English 17.6 KB
2025-10-10 08:00
Regulatory News Service
Update on Animal Health Program
English 19.0 KB
2025-10-09 08:00
Share Issue/Capital Change
Update, Equity Issue and PDMR Notification
English 35.1 KB
2025-10-02 13:37
Share Issue/Capital Change
Issue of Equity - Correction
English 33.2 KB
2025-10-02 08:59
Director's Dealing
Issue of Equity
English 32.5 KB
2025-09-19 13:40
Major Shareholding Notification
Holding(s) in Company
English 22.0 KB
2025-09-19 08:00
Regulatory News Service
Genflow Strengthens IP Portfolio
English 16.7 KB
2025-09-15 08:00
Regulatory News Service
Genflow Signs CDAs with Animal Health Companies
English 17.6 KB
2025-08-27 16:07
Major Shareholding Notification
Holding(s) in Company
English 21.7 KB
2025-08-18 08:00
Regulatory News Service
Company Update on Dog Trials
English 19.7 KB
2025-07-24 08:00
Earnings Release
Clinical Readiness Acceleration
English 17.7 KB
2025-07-17 08:00
Capital/Financing Update
Genflow Confirms Progression of Grant
English 18.0 KB
2025-06-12 11:16
Post-Annual General Meeting Information
Result of AGM
English 30.5 KB

Automate Your Workflow. Get a real-time feed of all GENFLOW BIOSCIENCES PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GENFLOW BIOSCIENCES PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GENFLOW BIOSCIENCES PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan 4893
NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea 244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea 382150

Talk to a Data Expert

Have a question? We'll get back to you promptly.